Form 8-K - Current report:
SEC Accession No. 0001641172-25-013368
Filing Date
2025-06-03
Accepted
2025-06-03 08:20:35
Documents
14
Period of Report
2025-06-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 36536
2 EX-99.1 ex99-1.htm EX-99.1 12459
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8887
  Complete submission text file 0001641172-25-013368.txt   232506

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE kapa-20250603.xsd EX-101.SCH 3026
5 XBRL LABEL FILE kapa-20250603_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE kapa-20250603_pre.xml EX-101.PRE 22366
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 251017219
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)